Series-C over 308 million euros for Tubulis

Tubulis, a Munich-based biotech company specializing in antibody drug conjugates (ADCs) for cancer therapy, has successfully raised EUR 308 million in a Series C financing round. Bayern Kapital is once again participating in the scale-up and will support the clinical development of Tubulis together with new investors such as Venrock Healthcare Capital Partners, Wellington Management and Ascenta Capital as well as existing investors Nextech Invest, EQT HTGF, Life Sciences, Frazier Life Sciences and other partners.

Targeted cancer therapy with antibody-drug conjugates

ADCs combine antibodies and drugs to target cancer cells and spare healthy tissue. This can reduce side effects and increase therapeutic efficiency. Tubulis is considered a pioneer in ADC development and is characterized in particular by the stability of its drug conjugates, which avoid previous losses before reaching the tumour cells.

Focus on leading candidates TUB-040 and TUB-030

The fresh capital will primarily flow into the further clinical development of the leading ADC candidate TUB-040, which is already undergoing Phase I/IIa trials and was granted fast-track status by the US FDA in June 2024. In addition, further candidates such as TUB-030 and the company's proprietary ADC platform technology are to be further developed in order to expand the pipeline and open up new treatment lines.

Tubulis exemplifies the performance of DeepTech companies from Bavaria and their global appeal

Monika Steger, Managing Director of Bayern Kapital

"The financing round enables us to realize our vision of differentiated ADCs that are adapted to the respective tumor indication and offer patients a high therapeutic added value," says Dr. Dominik Schumacher, CEO and co-founder of Tubulis.

Tubulis develops tailor-made ADCs with improved stability and targeted tumor accumulation. The most advanced programs are TUB-040 (targeting NaPi2b) and TUB-030 (targeting 5T4). The company aims to expand the applicability and therapeutic efficacy of this class of compounds and provide better treatment options for patients worldwide.